Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.62 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.49 |
| ▸ | GHSR | Q92847 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13900497 | 0.97 | SLC15A2 (0.58) | SLC15A2CPB2GHSRCYP3A4SLC7A5 | |
| SCHEMBL30409074 | 0.88 | SLC15A2 (0.71) | SLC15A2CPB2GHSRCYP3A4SLC7A5 | |
| SCHEMBL28027302 | 0.88 | SLC15A2 (0.71) | SLC15A2CPB2GHSRCYP3A4SLC7A5 | |
| SCHEMBL29444049 | 0.83 | SLC15A2 (0.65) | SLC15A2GHSR | |
| SCHEMBL26312334 | 0.82 | SLC15A2 (0.64) | SLC15A2CPB2GHSRCYP3A4SLC7A5 | |
| SCHEMBL29031268 | 0.81 | SLC15A2 (0.56) | SLC15A2CPB2CYP3A4SLC7A5 | |
| SCHEMBL30911281 | 0.81 | SLC15A2 (0.74) | SLC15A2CPB2GHSRCYP3A4SLC7A5 | |
| SCHEMBL27706632 | 0.81 | SLC15A2 (0.74) | SLC15A2CPB2GHSRCYP3A4SLC7A5 | |
| SCHEMBL19087236 | 0.81 | SLC15A2 (0.64) | SLC15A2CPB2CYP3A4SLC7A5REN | |
| SCHEMBL29349696 | 0.81 | SLC15A2 (0.64) | SLC15A2CPB2CYP3A4SLC7A5REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747264-A1 | MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE | University of Reading (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20250333423-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS | CARTHRONIX INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12268663-B2 | Method for treating pruritus | Pruvyc Pharma, LLC (US) | 2025-04-08 | — | — | US | disclosed |
| WO-2025037123-A1 | MICELLAR BIOACTIVE COLLAGEN-STIMULATING LIPOPEPTIDE | UNIVERSITY OF READING (GB) | 2025-02-20 | — | — | WO | disclosed |
| US-20230382903-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF | CARTHRONIX INC (US) | 2023-11-30 | — | — | US | disclosed |
| US-11826474-B2 | Nano-lipid carrier for encapsulation of bioactive material, and method for producing same | BINOTEC CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-20230210809-A9 | Method for Treating Pruritus | Pruvyc Pharma, LLC | 2023-07-06 | — | — | US | disclosed |
| US-20230085380-A1 | Method for Treating Pruritus | PRUVYC PHARMA LLC (US) | 2023-03-16 | — | — | US | disclosed |
| US-20220325072-A1 | ZWITTERIONIC CROSSLINKERS, HYDROGELS COMPRISING ZWITTERIONIC CROSSLINKERS, AND METHODS FOR MAKING AND USING | UNIVERSITY OF IDAHO | 2022-10-13 | — | — | US | disclosed |
| US-20220304903-A1 | METHOD OF PREPARING BIOACTIVE SUBSTANCE-ENCAPSULATED ETHOSOME, ETHOSOME COMPOSITION, AND COSMETIC COMPOSITION INCLUDING ETHOSOME COMPOSITION | BINOTEC CO., LTD. (KR) | 2022-09-29 | — | — | US | disclosed |
| US-11452679-B2 | Method of preparing bioactive substance-encapsulated ethosome, ethosome composition, and cosmetic composition including ethosome composition | BINOTEC CO., LTD. (KR) | 2022-09-27 | — | — | US | disclosed |
| US-20220265543-A1 | COSMETIC COMPOSITIONS AND USES THEREOF | ALUMIER LABS, INC. (CA) | 2022-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382903-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS, TOPICAL FORMULATIONS AND METHOD OF USE THEREOF | STAT1, STAT3, STAT6 | SLC15A2 2616/4885CPB2 4268/4885GHSR 283/4885 |
| US-20220265543-A1 | COSMETIC COMPOSITIONS AND USES THEREOF | CUTA, CERS2, GLA | SLC15A2 3160/4885CPB2 1003/4885GHSR 2415/4885 |
| US-20250333423-A1 | SMALL MOLECULE MODULATORS OF GP130 SIGNALING PATHWAYS | STAT3, STAT1, STAT4 | SLC15A2 4158/4885CPB2 4093/4885GHSR 417/4885 |
| US-20220325072-A1 | ZWITTERIONIC CROSSLINKERS, HYDROGELS COMPRISING ZWITTERIONIC CROSSLINKERS, AND METHODS FOR MAKING AND USING | ASS1, GFER, ASIC1 | SLC15A2 742/4885CPB2 3168/4885GHSR 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.